SCM
EBS icon

Stonepine Capital Management’s Emergent Biosolutions EBS Stock Holding History

Stonepine Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,000
Closed -$24.3K – 66
2025
Q1 		$24.3K Buy
+5,000
New +$41.4K 0.02% 63
2019
Q2 		– Sell
-46,800
Closed -$2.36M – 28
2019
Q1 		$2.36M Buy
+46,800
New +$2.76M 1.36% 20
2017
Q2 		– Sell
-54,505
Closed -$1.58M – 28
2017
Q1 		$1.58M Buy
+54,505
New +$1.66M 0.89% 18

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Stonepine Capital Management's EBS Position: Q2 2025 in Review

Stonepine Capital Management sold out of Emergent Biosolutions (EBS) in Q2 2025, closing a stake of 5,000 shares — an estimated $24.3K sold.

Stonepine Capital Management first reported a position in EBS in Q1 2017 and held it in 3 quarters. The position peaked at $2.36M in Q1 2019. 161 funds tracked by Wall St. Rank hold EBS as of Q2 2025.

  • Stonepine Capital Management reported no remaining Emergent Biosolutions position as of Q2 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 5,000 Emergent Biosolutions shares in Q2 2025, an estimated $24.3K.
  • Stonepine Capital Management first reported a position in Emergent Biosolutions in Q1 2017 and held it in 3 quarters.
  • Stonepine Capital Management's Emergent Biosolutions position peaked at $2.36M in Q1 2019.
  • 161 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2025.

Based on Stonepine Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.